2020
DOI: 10.1007/s40264-020-01002-6
|View full text |Cite|
|
Sign up to set email alerts
|

Assessing the Safety of COVID-19 Vaccines: A Primer

Abstract: Vaccines against COVID-19 are being developed at speeds not previously achieved. With this unprecedented effort comes challenges for post-marketing safety monitoring and challenges for vaccine safety communication. To deploy these new vaccines fast across diverse populations, it is vital that robust pharmacovigilance and active surveillance systems are in place. Not all countries have the capability or resources to undertake adequate surveillance and will rely on data from those who can. The tools exist to ass… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
34
0
4

Year Published

2020
2020
2023
2023

Publication Types

Select...
4
3
2

Relationship

0
9

Authors

Journals

citations
Cited by 43 publications
(39 citation statements)
references
References 29 publications
1
34
0
4
Order By: Relevance
“…A poll conducted in the USA in June 2020 showed only about 50% of Americans were committed to receiving a COVID-19 vaccine, with acceptance commitment among some communities being as low as 40% 29 . One possible explanation for our findings is that the vaccines against COVID-19 were developed at a record speed and in the context of an infodemic, both these factors can exacerbate heightened negative safety sentiments 30,31 . As the vaccination rollout continues globally, and with millions of doses administered in the first quarter of 2021, preliminary safety reports from the USA show COVID-19 vaccination results to mild adverse events and in rare cases, allergic reactions 32 .…”
Section: Discussionmentioning
confidence: 95%
“…A poll conducted in the USA in June 2020 showed only about 50% of Americans were committed to receiving a COVID-19 vaccine, with acceptance commitment among some communities being as low as 40% 29 . One possible explanation for our findings is that the vaccines against COVID-19 were developed at a record speed and in the context of an infodemic, both these factors can exacerbate heightened negative safety sentiments 30,31 . As the vaccination rollout continues globally, and with millions of doses administered in the first quarter of 2021, preliminary safety reports from the USA show COVID-19 vaccination results to mild adverse events and in rare cases, allergic reactions 32 .…”
Section: Discussionmentioning
confidence: 95%
“…This population is expected to find a high frequency of trust in COVID vaccines for two reasons: the first, emerging adults were included, and the second, being in higher education carriers. The findings are a strong wake-up call for educational and public health authorities to better understand student health education, particularly related to COVID-19, given the high safety and positive effects of the vaccination [29]. Health literacy is higher in the younger cohorts and people with more formal education years [13, 14, 30].…”
Section: Discussionmentioning
confidence: 99%
“…This may be attributable to the unprecedented time frame of vaccine development and approval. Vaccine development typically spans across 10–15 years from initial scientific discovery, preclinical and clinical studies, to licensure [ 5 ]. The sped-up timeline may be attributable to the rapid deployment of flexible vaccine platforms, generous funding, innovative trial designs and multinational cooperation.…”
Section: Introductionmentioning
confidence: 99%